CN109513043A - A kind of injection modification hyaluronic acid sodium gel and preparation method thereof - Google Patents
A kind of injection modification hyaluronic acid sodium gel and preparation method thereof Download PDFInfo
- Publication number
- CN109513043A CN109513043A CN201710877910.1A CN201710877910A CN109513043A CN 109513043 A CN109513043 A CN 109513043A CN 201710877910 A CN201710877910 A CN 201710877910A CN 109513043 A CN109513043 A CN 109513043A
- Authority
- CN
- China
- Prior art keywords
- hyaluronic acid
- gel
- acid sodium
- preparation
- microgel particle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/20—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/52—Hydrogels or hydrocolloids
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J3/00—Processes of treating or compounding macromolecular substances
- C08J3/02—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques
- C08J3/03—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques in aqueous media
- C08J3/075—Macromolecular gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/06—Flowable or injectable implant compositions
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2305/00—Characterised by the use of polysaccharides or of their derivatives not provided for in groups C08J2301/00 or C08J2303/00
- C08J2305/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Dermatology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a kind of injection modification hyaluronic acid sodium gels and preparation method thereof, belong to hyaluronic acid sodium gel technical field.This method is characterized in that hyaluronic acid and crosslinking agent 1,4- butanediol diglycidyl ether reacts to obtain water-insoluble gel under conditions of pH > 10, after broken, low-molecular-weight hyaluronic acid solution is added, after mixing, the reaction was continued, pH value is adjusted to neutrality, phosphate buffer solution is added, adjusts solid content, obtains injection modification hyaluronic acid sodium gel.This method is not necessarily to dialysis procedure, and gained injection, which modifies hyaluronic acid sodium gel, has good biocompatibility and stability, and is easy to inject, and can be used for beauty or medical field.
Description
Technical field
The present invention relates to hyaluronic acid sodium gel technical field, in particular to a kind of injection modifies hyaluronic acid sodium gel
And preparation method thereof.
Background technique
Hyaluronic acid (hyalouronic acid, HA) is made of glucuronic acid and n acetylglucosamine n disaccharide units
A kind of linear polymeric polysaccharide has splendid biological safety, is widely used in medical treatment and beauty treatment fields, HA has become at present
The soft tissue filler of usage amount first.
Since that there are degradation speeds is very fast for noncrosslinking HA gel, the disadvantage that the filling effect time is short, therefore normal open are maintained
It crosses cross-linking reaction and obtains crosslinking HA gel, to obtain more longlasting filling effect.Common crosslinking agent has: 1,4-butanediol two contracts
Water glycerin ether (Isosorbide-5-Nitrae-butanediol diglycidyl ether, BDDE) and divinylsulfone (divinyl sulfone,
DVS) etc..These crosslinking agents have very strong bio-toxicity, for the biological safety for ensureing gel, need strict control crosslinking HA solidifying
The content (< 2ppm) of crosslinking agent in glue.At present frequently with unreacted crosslinking agent in dialysis removal gel, dialysis procedure increases
Process flow and product cost are added.
A kind of preparation process for being crosslinked HA gel particle of the patented invention of Publication No. CN 101264348A, step
It include: cross-linking reaction preparation crosslinking HA gel；Dialysis treatment is crosslinked HA gel；Gel particle classification obtains crosslinking HA gel
Grain.Patent 1g is crosslinked HA gel and need to be dialysed 15~60 hours with the dialyzate of 500~5000ml, to remove unreacted crosslinking
Agent.
Publication No. CN 104086788A patent provides that a kind of dosage of crosslinking agent is few, injection of good rheological property is repaired
Adorn the preparation method of HA gel.It is characterized by: HA is reacted to obtain gel X with crosslinking agent under conditions of pH > 10；By HA with
Crosslinking agent reacts to obtain gel Y under conditions of pH > 9；Gel X is mixed with gel Y, cross-linking reaction is carried out again, through overregulating
PH value obtains injection modification HA gel to neutral and dialysis.Although this patent dosage of crosslinking agent is less, still needed to after cross-linking reaction
Dialysis treatment is carried out, crosslinking agent and unreacted small-molecule substance are removed.
Publication No. CN 103923328A discloses a kind of high quality cross-linking sodium hyaluronate gel and preparation method thereof,
After obtaining cross-linking hyaluronic acid sodium dry powder, washed with DMSO；By the powder ethanol washing after DMSO is washed；It will be through ethyl alcohol
The dry acquisition cross-linking hyaluronic acid sodium powder of powder under vacuum after washing；Powder is sufficiently swollen, is purified 6~10 hours in room temperature
Afterwards, homogeneous treatment with micron is carried out with high speed disperser, obtains cross-linking sodium hyaluronate gel particle.The method, which need to use, largely to be had
Machine reagent, there are the remaining risks of organic reagent, and preparation process is complicated.
But the above-mentioned prior art cannot have both, and preparation process is simple, product without dialysis purification, HA gel plasticity it is good and
The advantages that stable, internal retention time is long.
Summary of the invention
It cannot have both that preparation process is simple, product is without dialysis purification, HA to solve the HA gel of prior art preparation
Gel plasticity is good and stablize, the advantages that internal retention time is long the problem of, that the present invention provides a kind of preparation processes is simple, produces
Product are without dialysis purification, the injection modification HA gel that gel plasticity is good, stability is good, internal retention time is long and its side
Method.
The present invention is realized by following measures:
A kind of preparation method of injection modification hyaluronic acid sodium gel, includes the following steps:
(1) hyaluronic acid and 1,4-butanediol diglycidyl ether are mixed in 1.0~1.5% NaOH solution, in
30~50 DEG C insulation reaction 2-6 hours, obtain water-insoluble gel；
(2) gel for obtaining step (1) is broken, crosses 60 mesh screens, obtains microgel particle A；
(3) microgel particle A is uniformly mixed with the hyaluronic acid solution of low molecular weight, in 30~50 DEG C reaction 2-5 hours,
Obtain microgel particle B；
(4) microgel particle B is neutralized to system pH with 1.0~1.5% HCl solution is neutrality, obtains microgel particle C；
(5) microgel particle C is uniformly mixed with the phosphate buffer solution of pH=7, regulates and controls hyaluronic acid in microgel particle
Content be 16-20mg/mL；
(6) microgel particle that step (5) obtain is pressed through to the sieve of 120 mesh, it is filling in syringe, it is damp and hot in 121 DEG C
Sterilizing 15~20 minutes, obtains finished product.
The preparation method of the injection modification hyaluronic acid sodium gel, it is characterised in that hyaluronic acid in step (1)
Molecular weight be 1000~4000kDa.
The preparation method of the injection modification hyaluronic acid sodium gel, it is characterised in that hyaluronic acid in step (1)
Mass volume ratio with NaOH solution is 5%~30%, preferably 10%~20%.
The preparation method of the injection modification hyaluronic acid sodium gel, it is characterised in that Isosorbide-5-Nitrae-fourth two in step (1)
The mass ratio of alcohol diglycidyl ether and hyaluronic acid is 5~40%, preferably 5%~20%.
The preparation method of the injection modification hyaluronic acid sodium gel, it is characterised in that low molecular weight in step (3)
The molecular weight of hyaluronic acid is 1.0~5.0kDa, preferably 1.0~3.0kDa；Solution concentration be 0.5%~3%, preferably 1%~
2%.
The preparation method of the injection modification hyaluronic acid sodium gel, it is characterised in that microgel particle A in step (3)
Mass ratio with the hyaluronic acid solution of low molecular weight is 1: 1~4: 1, preferably 1: 1~2: 1.
A kind of injection modification hyaluronic acid sodium gel prepared such as above-mentioned preparation method.
The injection modifies hyaluronic acid sodium gel, it is characterised in that: the content of crosslinking agent B DDE is lower than in gel
2ppm。
The purpose of the present invention additionally provides the purposes of the gel, for filling fine, moderate or deep wrinkles, and tissue
Filling.
Beneficial effects of the present invention:
1. injection of the invention modifies hyaluronic acid sodium gel, there is good plasticity, be easy to inject, retains in vivo
Time is long, is able to maintain biocompatibility.
2. preparation process of the present invention is simple, product is not necessarily to dialysis purification, low energy consumption, and pollution-free, process cycle is short, is easy to produce
Industry metaplasia produces.
Specific embodiment
For a better understanding of the invention, it further illustrates combined with specific embodiments below.
Embodiment 1
(1) 5.0g hyaluronic acid (molecular weight 4000kDa) is dissolved in 50ml, in 1.0% NaOH solution, mixed
Afterwards, crosslinking agent 1,4-butanediol diglycidyl ether is added, crosslinking agent and hyaluronic acid mass ratio are 5%, are stirred and evenly mixed, 30
6h is reacted in DEG C water-bath, obtains water-insoluble gel；
(2) gel for obtaining step (1) is broken, crosses 60 mesh screens, obtains microgel particle A；
(3) by microgel particle A and 25ml, 1% hyaluronic acid (molecular weight 1.0kDa) solution is uniformly mixed, in 50
DEG C reaction 2 hours, obtain microgel particle B；
(4) microgel particle B is neutralized to system pH with 1.0% HCl solution is neutrality, obtains microgel particle C；
(5) microgel particle C is uniformly mixed with the phosphate buffer solution of pH=7, regulates and controls hyaluronic acid in microgel particle
Content be 16mg/mL；
(6) microgel particle that step (5) obtain is pressed through to the sieve of 120 mesh, it is filling in syringe, it is damp and hot in 121 DEG C
Sterilizing 15 minutes obtains injection modification hyaluronic acid sodium gel；
(7) gas chromatography of YY/T0962-2014 annex is used to measure BDDE residual quantity as 0.79ppm.
Embodiment 2
(1) 5.0g hyaluronic acid (molecular weight 1000kDa) is dissolved in 25ml, in 1.5% NaOH solution, mixed
Afterwards, crosslinking agent 1,4-butanediol diglycidyl ether is added, crosslinking agent and hyaluronic acid mass ratio are 20%, it stirs and evenly mixs,
2h is reacted in 50 DEG C of water-baths, obtains water-insoluble gel；
(2) gel for obtaining step (1) is broken, crosses 60 mesh screens, obtains microgel particle A；
(3) by microgel particle A and 25ml, 2% hyaluronic acid (molecular weight 1.0kDa) solution is uniformly mixed, in 30
DEG C reaction 5 hours, obtain microgel particle B；
(4) microgel particle B is neutralized to system pH with 1.5% HCl solution is neutrality, obtains microgel particle C；
(5) microgel particle C is uniformly mixed with the phosphate buffer solution of pH=7, regulates and controls hyaluronic acid in microgel particle
Content be 18mg/mL；
(6) microgel particle that step (5) obtain is pressed through to the sieve of 120 mesh, it is filling in syringe, it is damp and hot in 121 DEG C
Sterilizing 20 minutes obtains injection modification hyaluronic acid sodium gel；
(7) gas chromatography of YY/T0962-2014 annex is used to measure BDDE residual quantity as 1.26ppm.
Embodiment 3
(1) 5.0g hyaluronic acid (molecular weight 2000kDa) is dissolved in 35ml, in 1.25% NaOH solution, mixed
Afterwards, crosslinking agent 1,4-butanediol diglycidyl ether is added, crosslinking agent and hyaluronic acid mass ratio are 15%, it stirs and evenly mixs,
4h is reacted in 40 DEG C of water-baths, obtains water-insoluble gel；
(2) gel for obtaining step (1) is broken, crosses 60 mesh screens, obtains microgel particle A；
(3) by microgel particle A and 20ml, 1.5% hyaluronic acid (molecular weight 2.0kDa) solution is uniformly mixed, in
40 DEG C are reacted 3 hours, and microgel particle B is obtained；
(4) microgel particle B is neutralized to system pH with 1.25% HCl solution is neutrality, obtains microgel particle C；
(5) microgel particle C is uniformly mixed with the phosphate buffer solution of pH=7, regulates and controls hyaluronic acid in microgel particle
Content be 20mg/mL；
(6) microgel particle that step (5) obtain is pressed through to the sieve of 120 mesh, it is filling in syringe, it is damp and hot in 121 DEG C
Sterilizing 18 minutes obtains injection modification hyaluronic acid sodium gel；
(7) gas chromatography of YY/T0962-2014 annex is used to measure BDDE residual quantity as 0.87ppm.
Embodiment 4
(1) 5.0g hyaluronic acid (molecular weight 3000kDa) is dissolved in 40ml, in 1.0% NaOH solution, mixed
Afterwards, crosslinking agent 1,4-butanediol diglycidyl ether is added, crosslinking agent and hyaluronic acid mass ratio are 10%, it stirs and evenly mixs,
2h is reacted in 50 DEG C of water-baths, obtains water-insoluble gel；
(2) gel for obtaining step (1) is broken, crosses 60 mesh screens, obtains microgel particle A；
(3) by microgel particle A and 30ml, 1.5% hyaluronic acid (molecular weight 3.0kDa) solution is uniformly mixed, in
50 DEG C are reacted 2.5 hours, and microgel particle B is obtained；
(4) microgel particle B is neutralized to system pH with 1.5% HCl solution is neutrality, obtains microgel particle C；
(5) microgel particle C is uniformly mixed with the phosphate buffer solution of pH=7, regulates and controls hyaluronic acid in microgel particle
Content be 18mg/mL；
(6) microgel particle that step (5) obtain is pressed through to the sieve of 120 mesh, it is filling in syringe, it is damp and hot in 121 DEG C
Sterilizing 20 minutes obtains injection modification hyaluronic acid sodium gel；
(7) gas chromatography of YY/T0962-2014 annex is used to measure BDDE residual quantity as 0.93ppm.
The above embodiment is a preferred embodiment of the present invention, but embodiments of the present invention are not by the limit of embodiment
System, other any changes made without departing from the spirit and principles of the present invention, combination, substitution, simplification should be equivalent
Alternative is included within the scope of the present invention.
Claims (8)
1. a kind of preparation method of injection modification hyaluronic acid sodium gel, it is characterised in that include the following steps:
(1) hyaluronic acid and 1,4-butanediol diglycidyl ether are mixed in 1.0~1.5% NaOH solution, in 30~
50 DEG C insulation reaction 2-6 hours, obtain water-insoluble gel；
(2) gel for obtaining step (1) is broken, crosses the sieve of 60 mesh, obtains microgel particle A；
(3) microgel particle A is uniformly mixed with the hyaluronic acid solution of low molecular weight, in 30~50 DEG C reaction 2-5 hours, obtain solidifying
Glue particles B；
(4) microgel particle B is neutralized to system pH with 1.0~1.5% HCl solution is neutrality, obtains microgel particle C；
(5) microgel particle C is uniformly mixed with the phosphate buffer solution of pH=7, hyaluronic acid contains in regulation microgel particle
Amount is 16-20mg/mL；
(6) microgel particle that step (5) obtain is pressed through to the sieve of 120 mesh, it is filling in syringe, in 121 DEG C of moist heat sterilizations
15~20 minutes, obtain finished product.
2. a kind of preparation method of injection modification hyaluronic acid sodium gel according to claim 1, it is characterised in that step
Suddenly the molecular weight of hyaluronic acid is 1000~4000kDa in (1).
3. a kind of preparation method of injection modification hyaluronic acid sodium gel according to claim 1, it is characterised in that step
Suddenly hyaluronic acid and the mass volume ratio of NaOH solution are 5%~30% in (1).
4. a kind of preparation method of injection modification hyaluronic acid sodium gel according to claim 1, it is characterised in that step
Suddenly the mass ratio of 1,4-butanediol diglycidyl ether and hyaluronic acid is 5~40% in (1).
5. a kind of preparation method of injection modification hyaluronic acid sodium gel according to claim 1, it is characterised in that step
Suddenly the molecular weight of low-molecular-weight hyaluronic acid is 1~5kDa in (3), and solution concentration is 0.5%~3%.
6. a kind of preparation method of injection modification hyaluronic acid sodium gel according to claim 1, it is characterised in that step
Suddenly the mass ratio of microgel particle A and the hyaluronic acid solution of low molecular weight is 1: 1~4: 1 in (3).
7. injection prepared by preparation method according to claim 1 modifies hyaluronic acid sodium gel.
8. injection according to claim 7 modifies hyaluronic acid sodium gel, it is characterised in that: crosslinking agent B DDE in gel
Content be lower than 2ppm.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710877910.1A CN109513043A (en) | 2017-09-20 | 2017-09-20 | A kind of injection modification hyaluronic acid sodium gel and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710877910.1A CN109513043A (en) | 2017-09-20 | 2017-09-20 | A kind of injection modification hyaluronic acid sodium gel and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109513043A true CN109513043A (en) | 2019-03-26 |
Family
ID=65768616
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710877910.1A Pending CN109513043A (en) | 2017-09-20 | 2017-09-20 | A kind of injection modification hyaluronic acid sodium gel and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109513043A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112791238A (en) * | 2020-12-22 | 2021-05-14 | 浙江景嘉医疗科技有限公司 | Compound gel for treating bladder ureteral reflux and preparation method thereof |
| RU2750000C1 (en) * | 2019-12-25 | 2021-06-21 | Акционерное общество «Медтехнопроект» | Method for synthesis of modified hyaluronan and application thereof in medicine, including in endoprosthetics |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101538377A (en) * | 2008-03-20 | 2009-09-23 | 上海昊海生物科技有限公司 | Cross-linked hyaluronic acid gel and preparation method thereof |
| CN101759881A (en) * | 2008-10-08 | 2010-06-30 | 上海建华精细生物制品有限公司 | Medical cross-linking sodium hyaluronate gel derivative product and preparation method thereof |
| CN102065849A (en) * | 2008-04-24 | 2011-05-18 | 麦德托尼克公司 | Protective gel based on chitosan and oxidized polysaccharide |
| US20120225842A1 (en) * | 2010-01-13 | 2012-09-06 | Allergan, Inc. | Hyaluronic acid compositions for dermatological use |
| US20130209532A1 (en) * | 2007-11-30 | 2013-08-15 | Allergan, Inc. | Polysaccharide gel formulation having increased longevity |
| CN107029281A (en) * | 2017-04-17 | 2017-08-11 | 江苏昌吉永生物科技股份有限公司 | A kind of preparation method of Absorbable hemostatic material |
-
2017
- 2017-09-20 CN CN201710877910.1A patent/CN109513043A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130209532A1 (en) * | 2007-11-30 | 2013-08-15 | Allergan, Inc. | Polysaccharide gel formulation having increased longevity |
| CN101538377A (en) * | 2008-03-20 | 2009-09-23 | 上海昊海生物科技有限公司 | Cross-linked hyaluronic acid gel and preparation method thereof |
| CN102065849A (en) * | 2008-04-24 | 2011-05-18 | 麦德托尼克公司 | Protective gel based on chitosan and oxidized polysaccharide |
| CN101759881A (en) * | 2008-10-08 | 2010-06-30 | 上海建华精细生物制品有限公司 | Medical cross-linking sodium hyaluronate gel derivative product and preparation method thereof |
| US20120225842A1 (en) * | 2010-01-13 | 2012-09-06 | Allergan, Inc. | Hyaluronic acid compositions for dermatological use |
| CN107029281A (en) * | 2017-04-17 | 2017-08-11 | 江苏昌吉永生物科技股份有限公司 | A kind of preparation method of Absorbable hemostatic material |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2750000C1 (en) * | 2019-12-25 | 2021-06-21 | Акционерное общество «Медтехнопроект» | Method for synthesis of modified hyaluronan and application thereof in medicine, including in endoprosthetics |
| WO2021133190A1 (en) * | 2019-12-25 | 2021-07-01 | Акционерное общество "Медтехнопроект" | Method for producing modified hyaluronan |
| CN112791238A (en) * | 2020-12-22 | 2021-05-14 | 浙江景嘉医疗科技有限公司 | Compound gel for treating bladder ureteral reflux and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Silva et al. | Ionic liquids in the processing and chemical modification of chitin and chitosan for biomedical applications | |
| KR101868183B1 (en) | Process of preparing a cross linked gel | |
| CN103613686B (en) | The preparation method of thiolated hyaluronic acid and application thereof | |
| JP5657545B2 (en) | Method for preparing an injectable hydrogel crosslinked in an injectable container | |
| CN104771331B (en) | A kind of hyaluronic acid elastomer and its application | |
| US9872827B2 (en) | Cross-linked sodium hyaluronate gel for tissue filler for plastic surgery and preparation method thereof | |
| AU2014301493B2 (en) | A process for preparing a cross-linked hyaluronic acid product | |
| CN101502677B (en) | Crosslinking hyaluronic acid sodium gel for injection and preparation method thereof | |
| US11214656B2 (en) | Preparation method of cross-linked sodium hyaluronate gel | |
| HRP20160196T1 (en) | Viscoelastic gels as novel fillers | |
| WO2017136935A1 (en) | Dermal filler composed of macroporous chitosan microbeads and cross-linked hyaluronic acid | |
| CN107141519B (en) | A kind of modification of chitosan base superabsorbent hydrogel and its preparation and application | |
| WO2017016917A1 (en) | A process for efficient cross-linking of hyaluronic acid | |
| CN112851988B (en) | Preparation method of sodium hyaluronate gel | |
| CN109513043A (en) | A kind of injection modification hyaluronic acid sodium gel and preparation method thereof | |
| CN113278170B (en) | Chemically crosslinked hyaluronic acid hydrogel and preparation method and application thereof | |
| CN110016152A (en) | It is crosslinked the preparation method of filling hyaluronic acid sodium gel | |
| JP6561133B2 (en) | Biocompatible composition and method for producing the same | |
| CN110229357B (en) | Preparation method of cross-linked hyaluronic acid gel | |
| CN115737918B (en) | Injectable composite microsphere and preparation method thereof | |
| KR102226724B1 (en) | Preparing Method of Hyaluronic Acid Hydrogel by Physical Treatment | |
| CN113195600A (en) | Cross-linked polysaccharides and related methods | |
| EP3013866B1 (en) | A process for preparing a cross-linked hyaluronic acid product | |
| CN115671388A (en) | Performance-adjustable silk protein injectable microsphere gel and preparation method thereof | |
| CN115894969A (en) | Agarose-based hydrogel, and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20190326 |